Kintegral Advisory LLC Sells 517 Shares of DexCom, Inc. (NASDAQ:DXCM)

Kintegral Advisory LLC lowered its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 4.5% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 11,094 shares of the medical device company’s stock after selling 517 shares during the period. Kintegral Advisory LLC’s holdings in DexCom were worth $863,000 as of its most recent filing with the SEC.

A number of other large investors have also added to or reduced their stakes in the stock. Blue Whale Capital LLP grew its position in shares of DexCom by 91.9% during the 3rd quarter. Blue Whale Capital LLP now owns 236,000 shares of the medical device company’s stock valued at $15,821,000 after acquiring an additional 113,000 shares during the period. Brooktree Capital Management purchased a new position in DexCom in the third quarter valued at approximately $683,000. National Pension Service grew its holdings in DexCom by 4.1% during the third quarter. National Pension Service now owns 949,743 shares of the medical device company’s stock valued at $63,671,000 after purchasing an additional 37,363 shares during the period. Intact Investment Management Inc. purchased a new stake in DexCom in the third quarter worth $650,000. Finally, Motley Fool Asset Management LLC increased its position in DexCom by 168.7% in the third quarter. Motley Fool Asset Management LLC now owns 272,622 shares of the medical device company’s stock worth $17,993,000 after buying an additional 171,150 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on DXCM. Canaccord Genuity Group increased their price target on DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a research note on Friday, February 14th. Robert W. Baird upgraded shares of DexCom from a “neutral” rating to an “outperform” rating and increased their target price for the stock from $86.00 to $104.00 in a research report on Thursday, January 16th. Redburn Atlantic upgraded shares of DexCom from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $85.00 to $115.00 in a research note on Monday, February 3rd. Citigroup upped their price target on shares of DexCom from $85.00 to $91.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Finally, StockNews.com downgraded shares of DexCom from a “buy” rating to a “hold” rating in a report on Saturday, November 2nd. Four research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, DexCom presently has an average rating of “Moderate Buy” and an average target price of $99.06.

DexCom Stock Performance

Shares of DXCM opened at $88.78 on Friday. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. The stock has a 50-day moving average price of $83.50 and a 200-day moving average price of $76.06. The company has a market cap of $34.69 billion, a PE ratio of 62.08, a price-to-earnings-growth ratio of 2.30 and a beta of 1.14. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. As a group, equities analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Kevin R. Sayer sold 33,359 shares of the firm’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the transaction, the chief executive officer now directly owns 319,037 shares of the company’s stock, valued at approximately $27,727,505.67. This trade represents a 9.47 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, COO Jacob Steven Leach sold 2,634 shares of the business’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the sale, the chief operating officer now owns 268,644 shares of the company’s stock, valued at $23,347,850.04. The trade was a 0.97 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 38,083 shares of company stock worth $3,309,794. Corporate insiders own 0.30% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.